Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial
Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page
- Check5 days agoChange DetectedThe revision label on the page was updated from v3.6.2 to v3.6.3. This signals a minor page/template update rather than any changes to the study details.SummaryDifference0.0%

- Check12 days agoChange DetectedThe page revision tag changed from v3.6.0 to v3.6.2, representing an internal update to the ClinicalTrials.gov page. Substantive study information remains unchanged.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRecruitment status updated to No longer looking for participants, indicating the study is not enrolling. New help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment heading was adjusted for consistency.SummaryDifference0.3%

- Check34 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous v3.5.4. This reflects a small update to the page's revision history rather than any substantive change to study details or navigation.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page’s revision metadata was updated from v3.5.3 to v3.5.4, indicating an internal platform update. There is no indication that the study content or user-facing information was altered.SummaryDifference0.0%

- Check77 days agoChange DetectedThe page’s displayed revision/version number has been updated from **v3.5.2** to **v3.5.3**. This reflects a site or interface release rather than a change to the clinical trial information.SummaryDifference0.0%

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.